Solana Foundation President Predicts Growth of Internet

Monnalisa’s delisting from trading on Euronext Growth Milan took effect today. The company is preparing a shareholder buyback process led by Modamet and Jafin Due for investors seeking to sell. Further details are due in coming days on the purchase window and a single settlement date for the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monnalisa S.p.A. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.

Updated stock data and added analyst comments in paragraphs 8 and 10 Christy Santhosh - Reuters, October 6 - ArriVent BioPharma (AVBP.O) announced on Tuesday that its oral therapy for a rare form of lung cancer failed to significantly delay disease progression in a late-stage clinical trial, causing the company's share price to plunge by nearly 60% in early trading. The therapy, firmonertinib, was tested in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients carrying a gene mutation known as EGFR exon 20 insertion, which may promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC makes up around 85% of all lung cancer cases. An assessment by independent reviewers showed that ArriVent’s 240 mg dose therapy extended median progression-free survival to 11 months in the trial, compared to just 9.5 months for the chemotherapy group. CEO Bing Yao stated that the improvement in progression-free survival (i.e., the period during which a patient's cancer does not worsen or spread) was not "significant". "These disappointing results are not what we had hoped for, especially for patients who... are in urgent need of more effective treatment options." The company said it is reviewing the complete dataset to determine the most appropriate development path for firmonertinib, and no new safety signals were observed in the trial. BTIG analyst Jeet Mukherjee noted that the main reason the trial appears to have failed was the control group's performance exceeding expectations—their progression-free survival reached 9.5 months, when only 7.5 to 8 months was anticipated; firmonertinib’s 11-month result matched the expected range of 9 to 11 months. Additionally, firmonertinib is currently undergoing an advanced clinical trial in NSCLC patients with rare EGFR PACC mutations in their tumors. "This result is a significant setback for the exon 20 mutation treatment space, but the PACC program still has clinical support," said Clear Street analyst Kaveri Pohlman. The therapy has been approved in China for NSCLC patients carrying specific mutations. (To aid non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these translated texts and they are provided for reader convenience only. Reuters is not responsible for any damages or losses arising from the use of automated translation features.)